指南与共识慢性肾脏病肾血管病与高血压

肾脏病患者的心力衰竭管理——2021年ESC指南更新

Management of heart failure in patients with kidney disease-updates from the 2021 ESC guidelines.
指南 / 共识 · Nephrol Dial Transplant · 2023-01-01

2021年欧洲心脏病学会指南更新了心力衰竭管理,强调识别三种心衰表型以指导循证治疗,提出射血分数降低心衰的简化治疗流程(四类支柱药物快速序贯启动与上调),并调整了器械治疗指征,同时更新了包括慢性肾脏病在内的非心血管合并症相关心衰的治疗方案。

要点

  • 2021年ESC指南强调识别三种心衰表型以指导循证管理。
  • 射血分数降低心衰采用四类支柱药物快速序贯启动与上调。
  • 非缺血性心衰的一级预防ICD及QRS<150 ms合并LBBB的CRT指征被下调。

核心结论

  • 2021年ESC指南更新了心衰管理,肾脏病学家应熟悉其内容以应对CKD与慢性心衰的重叠。

研究设计与样本

  • 本文为对2021年欧洲心脏病学会心衰指南的解读,聚焦肾脏病患者。

主要发现

  • 2021年指南较2016年版更强调识别三种心衰表型以指导循证管理。
  • 射血分数降低心衰采用简化的四支柱药物快速序贯启动与上调流程。
  • 非缺血性心衰的一级预防ICD及QRS<150 ms合并LBBB的CRT指征被下调。
  • 更新了包括CKD在内的非心血管合并症相关心衰的治疗方案。

关键数值与推荐

  • 四支柱药物包括血管紧张素转换酶抑制剂或血管紧张素-脑啡肽酶抑制剂、β受体阻滞剂、盐皮质激素受体拮抗剂及钠-葡萄糖共转运蛋白2抑制剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The wide overlap between the syndromes of chronic kidney disease (CKD) and chronic heart failure (HF) means that familiarity with the 2021 European Society of Cardiology guidelines is of importance to nephrologists. The common risk factors for the two syndromes together with the adverse cardiac structural remodelling associated with CKD means that many kidney disease patients experience breathlessness and fall within the HF phenotypes categorized in the guidelines. The management of HF is evolving rapidly leading to significant changes in the latest guideline iteration. The 2021 guidelines have changed from the 2016 version firstly by an increased focus on identifying the three phenotypes of HF to guide appropriate evidence-based management. Secondly, a new and simplified treatment algorithm for HF with reduced ejection fraction involving the rapid sequential initiation and up-titration of four 'pillars' of drug treatment-angiotensin-converting enzyme inhibitors or angiotensin-neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists and now, thanks to convincing trial data, sodium-glucose co-transporter 2 inhibitors. Thirdly, guidelines for device therapy have been changed with down-graded advice on indications for primary prevention implantable cardioverter defibrillator therapy for patients with non-ischaemic HF and for cardiac resynchronization therapy with left bundle branch block (LBBB) and a QRS duration <150 ms. There are updated treatment plans for HF associated with non-cardiovascular comorbidities including CKD.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Edwards NC, Price AM, Steeds RP, et al. Management of heart failure in patients with kidney disease-updates from the 2021 ESC guidelines. Nephrol Dial Transplant. 2023. PMID: 36690349. doi:10.1093/ndt/gfad011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。